Get startedLog in
    Picture of BioMarin Pharmaceutical logo

    BMRN — BioMarin Pharmaceutical News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapNeutral
    All News

    Brief: Biomarin Announces Positive Pivotal Phase 3 Data For Palynziq® (Pegvaliase-Pqpz) In Adolescents With Phenylketonuria At 15th International Congress Of Inborn Errors Of Metabolism

    Picture of BioMarin Pharmaceutical logoBioMarin Pharmaceutical
    06/09/2025 16:22
    Sept 6 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:

BIOMARIN ANNOUNCES POSITIVE PIVOTAL PHASE 3 DATA FOR PALYNZIQ® (PEGVALIASE-PQPZ) IN ADOLESCENTS WITH PHENYLKETONURIA AT 15TH INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM

BIOMARIN PHARMACEUTICAL INC - PHASE 3 STUDY SHOWS 49.7% DECREASE IN BLOOD PHE LEVELS

Source text: ID:nPn8clHNPa

Further company coverage: BMRN.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on BioMarin Pharmaceutical

    See all news